This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Bladder cancer	Phosphoinositide 3-kinase catalytic subunit α -polypeptide (PIK3CA; p110 α); protein kinase B γ (PKBG; AKT3); fibroblast growth factor receptor 3 (FGFR3; CD333); HER2 (EGFR2; ErbB2; neu); epidermal growth factor receptor 3 (EGFR3; HER3; ErbB3)	Genomic studies suggest antagonists of PIK3CA, AKT3, FGFR3, HER2 or HER3 could be useful for treating bladder cancer. Whole-genome and RNA sequencing of 131 urothelial bladder cancer biopsies identified activating mutations or amplifications in the above targets or related pathways in approximately 69% of tumors. Next steps could include classifying patient tumors based on mutations and testing mutation-matched inhibitors <i>in vitro</i> and in animal models. At least 60 products are marketed or in development that target these proteins to treat a range of tumor types.	Patent and licensing status undisclosed	The Cancer Genome Atlas Research Network. <i>Nature</i> ; published online Jan. 29, 2014; doi:10.1038/nature12965 Contact: John N. Weinstein, The University of Texas MD Anderson Cancer Center, Houston, Texas e-mail: jweinste@mdanderson.org
		<i>SciBX</i> 7(9); doi:10.1038/scibx.2014.248 Published online March 6, 2014		